Ovid De-Risks Its Phase III Angelman Program With EU Angelini Partnership
You may also be interested in...
Ultragenyx is buying its Angelman syndrome partner GeneTx for $75m on the heels of an interim Phase I/II readout that shows signs of clinical activity and appears to resolve earlier safety worries.
The Phase III clinical trial showed a noticeable placebo effect compared with OV101.
A Phase II trial of the CH24H inhibitor showed a statistically significant benefit in children with the rare epilepsy syndrome Dravet Syndrome, but not in Lennox-Gastaut syndrome (LGS).